1. Home
  2. LEE vs KPTI Comparison

LEE vs KPTI Comparison

Compare LEE & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEE
  • KPTI
  • Stock Information
  • Founded
  • LEE 1890
  • KPTI 2008
  • Country
  • LEE United States
  • KPTI United States
  • Employees
  • LEE N/A
  • KPTI N/A
  • Industry
  • LEE Newspapers/Magazines
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEE Consumer Discretionary
  • KPTI Health Care
  • Exchange
  • LEE Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • LEE 90.6M
  • KPTI 81.1M
  • IPO Year
  • LEE N/A
  • KPTI 2013
  • Fundamental
  • Price
  • LEE $12.20
  • KPTI $0.63
  • Analyst Decision
  • LEE
  • KPTI Strong Buy
  • Analyst Count
  • LEE 0
  • KPTI 4
  • Target Price
  • LEE N/A
  • KPTI $5.00
  • AVG Volume (30 Days)
  • LEE 30.2K
  • KPTI 678.9K
  • Earning Date
  • LEE 02-06-2025
  • KPTI 02-27-2025
  • Dividend Yield
  • LEE N/A
  • KPTI N/A
  • EPS Growth
  • LEE N/A
  • KPTI N/A
  • EPS
  • LEE N/A
  • KPTI N/A
  • Revenue
  • LEE $600,264,000.00
  • KPTI $148,442,000.00
  • Revenue This Year
  • LEE N/A
  • KPTI $5.47
  • Revenue Next Year
  • LEE N/A
  • KPTI $6.33
  • P/E Ratio
  • LEE N/A
  • KPTI N/A
  • Revenue Growth
  • LEE N/A
  • KPTI 1.77
  • 52 Week Low
  • LEE $7.57
  • KPTI $0.58
  • 52 Week High
  • LEE $19.63
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • LEE 36.69
  • KPTI 46.51
  • Support Level
  • LEE $11.87
  • KPTI $0.60
  • Resistance Level
  • LEE $13.69
  • KPTI $0.70
  • Average True Range (ATR)
  • LEE 0.92
  • KPTI 0.05
  • MACD
  • LEE 0.01
  • KPTI -0.00
  • Stochastic Oscillator
  • LEE 19.18
  • KPTI 46.61

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: